Is a High Baseline Inflammatory Burden the Major Driver in Causing Daptomycin-induced Eosinophilic Pneumonia and Muscular Toxicity?

Competing Interests: Potential conflicts of interest. M. G. reports grants from Angelini S.p.A.; payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events from Angelini S.p.A.; and support for attending meetings and/or travel from Gilead, outside the submitted work. F. P. reports personal fees from Angelini, Basilea Pharmaceutica, Gilead, Hikma, MSD, Pfizer, Sanofi-Aventis, Shionogi, ThermoFisher, and Accelerate Diagnostics, outside the submitted work; has participated in speaker's bureaus for Accelerate Diagnostics, Angelini S.p.A., Basilea Pharmaceutica, Gilead, Hikma, MSD, Pfizer, Sanofi-Aventis, Shionogi, and ThermoFisher, and as a consultant for Angelini, Basilea Pharmaceutica, Gilead, MSD, Pfizer, and Shionogi, outside the submitted work. Both authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.